Post-Treatment Controllers & HIV Treatment
Control Issues
What can post-treatment controllers tell us about HIV care and treatment?
by Jeannie Wraight
In order to keep their virus suppressed, most people living with...
Trump Strives to End HIV, But at Whose Expense?
A Plan for America
The Trump administration strives to end the HIV epidemic, but at whose expense?
by Jeannie Wraight
In this month’s Destination: Cure I’m going...
JAK Inhibitors
JAK of All Trades
Researchers look to JAK inhibitors as part of hiv treatment & eradication
by Jeannie Wraight
R research on three Janus kinase inhibitors (JAK...
BIT225: HIV VPU Inhibitor Candidate
Contender in the Ring
A novel HIV therapy targets & eradicates one cell type in the viral reservoir
by Jeannie Wraight
BIT225, an HIV VPU inhibitor, has...
HIV reportedly “cured” in patient in London
For only the second time in the history of the AIDS pandemic, a patient with HIV in London seems to have been freed of...
Translation Inhibitors as Therapeutic Strategy
Cure Research with a Heart
Translation inhibitors may be part of a therapeutic strategy
by Jeannie Wraight
To date there are over 100 documented cases of HIV...
RIVER Study: Kick & Kill Vaccine Strategy
RIVER Dry
Kick and kill strategy study yields disappointing results
by Jeannie Wraight
Latent HIV resides in cells in blood and tissue which we collectively call the...
APPROACH Study
Mosaic Design
APPROACH, a preventive vaccine study, seeks to address more than one clade
by Jeannie Wraight
Over the past thirty-plus years, strategies such as Treatment as...
Broadly Neutralizing Antibodies
Another Road
Broadly neutralizing antibodies aim for a diverse effect against HIV types
by Jeannie Wraight and David Miller
Broadly neutralizing antibodies (bNAbs) hold the potential of...
Toxoplasmosis & HIV
A new study published in the Journal of Immunology suggests that co-infection with toxoplasmosis (toxo), a parasitic infection common in people with AIDS, may...